International Myeloma Working Group member Saad Z. Usmani, MD, Director of Plasma Cell Disorder program and the Director of Clinical Research in Hematologic Malignancies at Levine Cancer Institute/Carolinas Healthcare System in Charlotte, North Carolina, describes the importance of the Freelite® and Hevylite® assays for monitoring multiple myeloma in two new videos.
In “The Role of Freelite® in Assessment of Stringent Complete Response (sCR),” Dr. Usmani explains what stringent complete response is, why it is important to understand the depth of response for myeloma patients, and the Freelite assay’s role in quantifying free light chains in the blood stream. This test provides one of the important measurements for determining stringent complete response.
In the second video, “Use of Hevylite® in Routine Clinical Practice,” Dr. Usmani describes how the Hevylite assay measures the ratio of immunoglobulin subtypes (made up of heavy chain and light chain pairs) and why this measurement is an important marker for myeloma monitoring. Dr. Usmani explains that the measurement can be useful in monitoring: smoldering myeloma to detect early signs of progression, treatment response, and the disease in general to detect progression or relapse.
To learn more about these important measurements, read the IMF’s Understanding Serum Free Light Chain and Serum Heavy/Light Chain Assays and the IMF’s Freelite®/ Hevylite® Tip Card
The Role of Freelite® in Assessment of Stringent Complete Response (sCR)
Use of Hevylite® in Routine Clinical Practice